Cargando…

Preferences of Adult Patients With Inflammatory Bowel Disease for Attributes of Clinical Trials: Evidence From a Choice-Based Conjoint Analysis

BACKGROUND: Clinical trial recruitment is the rate-limiting step in developing new treatments. To understand inflammatory bowel disease (IBD) patient recruitment, we investigated two questions: Do changes in clinical trial attributes, like monetary compensation, influence recruitment rates, and does...

Descripción completa

Detalles Bibliográficos
Autores principales: Wood, Dallas, Kosa, Katherine, Brown, Derek, Ehrlich, Orna G, Higgins, Peter D R, Heller, Caren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802344/
https://www.ncbi.nlm.nih.gov/pubmed/36777964
http://dx.doi.org/10.1093/crocol/otz048
Descripción
Sumario:BACKGROUND: Clinical trial recruitment is the rate-limiting step in developing new treatments. To understand inflammatory bowel disease (IBD) patient recruitment, we investigated two questions: Do changes in clinical trial attributes, like monetary compensation, influence recruitment rates, and does this influence differ across subgroups? METHODS: We answered these questions through a conjoint survey of 949 adult IBD patients. RESULTS: Recruitment rates are influenced by trial attributes: small but significant increases are predicted with lower placebo rates, reduced number of endoscopies, less time commitment, open label extension, and increased involvement of participant’s primary GI physician. A much stronger effect was found with increased monetary compensation. Latent class analysis indicated three patient subgroups: some patients quite willing to participate in IBD trials, some quite reluctant, and others who can be persuaded. The persuadable group is quite sensitive to monetary compensation, and payments up to US$2,000 for a 1-year study could significantly increase recruitment rates for IBD clinical trials. CONCLUSIONS: This innovative study provides researchers with a framework for predicting recruitment rates for different IBD clinical trials.